Incyte (NASDAQ:INCY) Stock

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

wall street shutter6

Equities

Government

Large Cap

Macro Economic Events

Regulations

Commodities

Econ #s

Economics

Tech

ETFs

$BTC

AIOT

CENX

SPDR Dow Jones Industrial Average ETF Trust

GCMG

INCY

KALU

MNDY

NVDA

ROIV

STLD

Select Sector SPDR-Consumer Discretionary

Wall Street bounced back on Monday, recovering from Friday&#39;s robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while awaiting further clarity on trade policie

Tech Stocks Surge, Steelmakers Jump On Trump&#39;s 25% Tariffs, Copper Hits 9-Month Highs: What&#39;s Driving Markets Monday?

incy

Analyst Color

Biotech

Earnings

News

Guidance

Health Care

Analyst Ratings

Movers

General

Incyte projects 2025 Jakafi revenue of $2.925B-$2.975B, up 4.76%-6.55%, and Opzelura sales of $630M-$670M, reflecting up to 31.81% growth.

Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches

incy copy

Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.

Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline

Incyte Corp

Incyte And Genesis Therapeutics Enter Into Strategic AI-Focused Research Collaboration

Rumors

Watching Incyte Shares, Hearing M&A Blog Mentions Merck As Potential Buyer

JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Market Perform to Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Incyteto Market Perform

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and lowers the price target from $70 to $68.

Price Target

RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $68

WIIM

Incyte shares are trading lower after Citigroup cut its price target on the stock from $97 to $88.

In the last three months, 7 analysts have published ratings on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $76.57, with a high estimate of $88.00 and a low estimate of $70.00. Observing a downward trend, the current average is 0.56% lower than the prior average price target of $77.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739278834_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Incyte by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$77.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$77.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$74.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Incyte's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Incyte's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>Unveiling the Story Behind Incyte</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>A Deep Dive into Incyte's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.81%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Incyte's net margin excels beyond industry benchmarks, reaching 9.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Incyte's ROE stands out, surpassing industry averages. With an impressive ROE of 3.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.2%, the company showcases effective utilization of assets.
Debt Management: Incyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Incyte Stock

Citigroup analyst David Lebowitz maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Buy and lowers the price target from $97 to $88.

Citigroup Maintains Buy on Incyte, Lowers Price Target to $88

Wall Street bounced back on Monday, recovering from Friday's robust decline fueled by tariff concerns, as investors remained focused on strong earnings from the fourth-quarter reporting season while awaiting further <a href="https://www.benzinga.com/government/regulations/25/02/43596413/corporate-americas-best-earnings-in-3-years-will-tariffs-end-wall-streets-honeymoon">clarity on trade policies.</a>
The Nasdaq 100 jumped 1.3% by midday in New York, poised for its best session in over three weeks, with semiconductor stocks leading the charge. 
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 3.4%, buoyed by a Wall Street Journal <a href="https://www.wsj.com/articles/new-york-state-bans-deepseek-from-government-devices-de7a9df4">report</a> announcing that New York State banned DeepSeek from government devices, sparking speculation about stricter state regulations on Chinese AI chip products.
Steel and aluminum stocks rallied after President Donald Trump announced plans to impose a 25% tariff on imports of both <a href="https://www.benzinga.com/government/regulations/25/02/43592144/us-steel-aluminum-stocks-rally-as-trump-revives-25-tariff-plan">metals from all countries.</a>
<ul>
<li>United States Steel Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) rose 4.7%, eyeing its best session in a month.</li>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) climbed 5.5%.</li>
<li>Century Aluminum Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) jumped 10.4%, while Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) gained 6.5%.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) soared 17.3%, Alcoa Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) rose 3.6%, and Kaiser Aluminum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) added 2.9%.</li>
</ul>
Commodities rallied, with metals and energy producers outperforming. Gold extended record highs with a 1.5% gain, but copper stole the spotlight, surging 2.6% to its highest level since May 2024, marking its sixth consecutive daily gain. Oil prices also rebounded, rising over 1%.
Crypto sentiment improved slightly, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) gaining 1% to $97,500 after a period of subdued price action.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,778.76</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,069.92</td>
<td>0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,291.54</td>
<td>0.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,437.68</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.7% to $604.81.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) inched 0.3% up to $444.50.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 1.3% to $529.73.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.6% to $227.25.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2%; the&nbsp;Financials Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 0.7%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included:
<ul>
<li>McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): up 3.8%</li>
<li>Rockwell Automation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>): up 12.8%</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>): down 6.6%</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>): up 30.3%</li>
<li>Insperity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>): up 14.7%</li>
<li>Edgewell Personal Care Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>): down 9.7%</li>
<li>CNA Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>): up 2.1%</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): down 6.0%</li>
<li>Roivant Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>): up 1.1%</li>
<li>GCM Grosvenor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>): up 3.8%</li>
<li>PowerFleet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>): up 32.3%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/02/43600852/china-sets-sights-on-us-tech-companies-as-trade-tensions-rise">China Sets Sights On Apple, Nvidia And Other US Tech Companies As Trade Tensions Rise</a></li>
</ul>
Photo: Shutterstock

Tech Stocks Surge, Steelmakers Jump On Trump's 25% Tariffs, Copper Hits 9-Month Highs: What's Driving Markets Monday?

Deep-pocketed investors have adopted a bullish approach towards Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in INCY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Incyte. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $414,097, and 5 are calls, amounting to $303,700.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $72.5 to $95.0 for Incyte during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Incyte's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Incyte's substantial trades, within a strike price spectrum from $72.5 to $95.0 over the preceding 30 days.
<h3>Incyte Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739211319_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INCY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.3</td>
<td>$4.3</td>
<td>$4.0</td>
<td>$72.50</td>
<td>$240.0K</td>
<td>1.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>INCY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.0</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$72.50</td>
<td>$107.3K</td>
<td>1.3K</td>
<td>281</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$4.8</td>
<td>$3.4</td>
<td>$4.2</td>
<td>$95.00</td>
<td>$84.0K</td>
<td>368</td>
<td>300</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.9</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$80.00</td>
<td>$68.0K</td>
<td>833</td>
<td>501</td>
</tr>
<tr>
<td>INCY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.3</td>
<td>$3.5</td>
<td>$4.2</td>
<td>$72.50</td>
<td>$66.7K</td>
<td>1.3K</td>
<td>440</td>
</tr>
</tbody>
</table>

<h3>About Incyte</h3>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
After a thorough review of the options trading surrounding Incyte, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Incyte</h3>
<ul>
<li>Currently trading with a volume of 1,924,101, the INCY's price is down by -6.46%, now at $69.34. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Incyte with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Incyte Unusual Options Activity

Incyte shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS estimate.

On Monday,&nbsp;Incyte&nbsp;Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) reported&nbsp;fourth-quarter revenue&nbsp;of $1.18 billion, up 16% year over year and beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.14 billion</a>.
The company reported an adjusted EPS of $1.43, which was up from $1.06 a year ago and missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43588372/incyte-reports-2024-fourth-quarter-and-year-end-financial-results-provides-2025-financial-guidance" rel="noreferrer noopener">consensus estimate of $1.56</a>.
Jakafi&#8217;s net product revenue increased 11% to $773.1 million, primarily due to a 14% increase in paid demand.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42974065/incyte-at-jpm25-eyes-transformational-2025-with-multiple-drug-launches-and-expanding-pipeline" rel="noreferrer noopener">Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline</a>
Opzelura net product revenue increased 48% to $161.6 million, driven by continued growth in new patient starts and refills in the U.S. and increased contribution from Europe.
Minjuvi/Monjuvi net product revenue increased 265% to $32.81 million, as the company recognized all revenue from sales of Monjuvi in the United States following the acquisition of exclusive global rights for tafasitamab in February 2024.
&#8220;2024 was an important year for Incyte, with a 15% increase in total revenues, driven by strong growth from both Jakafi and Opzelura, as well as significant progress across our R&amp;D pipeline,&#8221; said Hervé Hoppenot, Chief Executive Officer, Incyte.
Guidance: Incyte forecasts 2025 Jakafi revenue of $2.925 billion-$2.975 billion, up 4.76%-6.55% from 2024.
Opzelura sales are expected to increase between 23.9%-31.81% to $630 million-$670 million.
&#8220;Looking ahead to 2025, we anticipate a year of continued strong revenue growth and diversification, as well as several defining milestones that will serve as an inflection point for Incyte. A year ago, we set the goal to achieve more than 10 impactful product launches by 2030. In 2025, a number of key catalysts across the entire portfolio will bring that goal closer to reality,&#8221; Hoppenot added.
Incyte says 2025 is expected to be a year of defining catalysts with four launches, four pivotal study readouts, at least three Phase 3 study initiations, and seven proof-of-concept study readouts.
William Blair writes, &#8220;We continue to see steady growth of Jakafi in approved indications and believe that ongoing studies for lifecycle management could provide upside to current peak sales and offer the potential to extend Jakafi franchise exclusivity. We believe that Opzelura should provide Incyte with an additional meaningful commercial opportunity in large immune dermatological indications. Povorcitinib remains underappreciated by investors and has the potential to be a major value driver by the end of this decade.&#8221;
The analyst Matt Phipps reiterates <a target="_blank" href="https://www.benzinga.com/quote/INCY/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
In November, Incyte&nbsp;announced that it would pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42069374/incytes-750-million-escient-deal-faces-setback-with-toxicology-issues-in-two-investigational-drugs-analyst-flags-challenges" rel="noreferrer noopener">spontaneous urticaria (CSU)</a>.
The decision was made following the observation of certain in vivo preclinical toxicology findings.
Price Action:&nbsp;INCY stock is down 6.79% at $69.10 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43570221/analysts-see-positive-momentum-for-expedia-on-strong-q4-earnings" target="_blank" rel="noreferrer noopener">Expedia&#8217;s Travel Momentum Grows, But Analysts Await Clearer Signs Of Long-Term Upside</a></li>
</ul>

The earnings results for Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) for Q4 were made public on Monday, February 10, 2025 at 07:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Incyte missed estimated earnings by -8.0%, reporting an EPS of $1.43 versus an estimate of $1.55.
Revenue was up $166.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company missed on EPS by $0.02 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Incyte's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.09</td>
<td>-1.55</td>
<td>0.84</td>
<td>1.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.07</td>
<td>-1.82</td>
<td>0.64</td>
<td>1.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.08B</td>
<td>1.01B</td>
<td>926.53M</td>
<td>1.00B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.14B</td>
<td>1.04B</td>
<td>880.89M</td>
<td>1.01B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Incyte <a href="https://www.benzinga.com/quote/INCY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Incyte Q4 Earnings

Incyte Forecasts 2025 Jakafi Revenue Of $2.925B-$2.975B And Opzelura Sales Of $630M-$670M

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) reported quarterly earnings of $1.43 per share which missed the analyst consensus estimate of $1.56 by 8.33 percent. This is a 34.91 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.14 billion by 3.16 percent. This is a 16.39 percent increase over sales of $1.01 billion the same period last year.

Incyte Q4 2024 Adj EPS $1.43 Misses $1.56 Estimate, Sales $1.18B Beat $1.14B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $431.01 million. 
• Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) is expected to report quarterly earnings at $0.79 per share on revenue of $261.34 million. 
• Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) is expected to report quarterly earnings at $0.53 per share on revenue of $387.09 million. 
• Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $480.16 million. 
• McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) is estimated to report quarterly earnings at $2.86 per share on revenue of $6.48 billion. 
• Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) is projected to report quarterly earnings at $1.55 per share on revenue of $1.15 billion. 
• CSP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSPI#NASDAQ">CSPI</a>) is estimated to report earnings for its first quarter. 
• Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) is likely to report quarterly loss at $0.03 per share on revenue of $59.50 million. 
• Motorcar Parts of America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPAA#NASDAQ">MPAA</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $179.50 million. 
• Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) is likely to report quarterly loss at $0.22 per share on revenue of $5.00 million. 
• Insperity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $1.60 billion. 
• GCM Grosvenor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $158.60 million. 
• Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) is likely to report quarterly earnings at $1.67 per share on revenue of $1.88 billion. 
• PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIOT#NASDAQ">AIOT</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $99.43 million. 
• ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) is expected to report quarterly earnings at $0.98 per share on revenue of $1.76 billion. 
• Alexander's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALX#NYSE">ALX</a>) is estimated to report quarterly earnings at $3.71 per share on revenue of $55.20 million. 
• Loews (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) is expected to report earnings for its fourth quarter. 
• CNA Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $3.62 billion. 
• ORIX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IX#NYSE">IX</a>) is estimated to report earnings for its third quarter. 
<h3>Companies Reporting After The Bell</h3>
• Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) is expected to report quarterly earnings at $1.80 per share on revenue of $3.95 billion. 
• RCI Hospitality Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RICK#NASDAQ">RICK</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.82 million. 
• Ark Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKR#NASDAQ">ARKR</a>) is expected to report earnings for its first quarter. 
• Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) is projected to report earnings for its first quarter. 
• Radiant Logistics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RLGT#AMEX">RLGT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $220.60 million. 
• Cresud SACIF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRESY#NASDAQ">CRESY</a>) is likely to report earnings for its second quarter. 
• Prospect Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSEC#NASDAQ">PSEC</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $189.67 million. 
• SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $447.00 million. 
• SPDR ICE Preferred Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSK#NYSE">PSK</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $121.00 million. 
• PetMed Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $60.00 million. 
• Quipt Home Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) is likely to report earnings for its first quarter. 
• RGC Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGCO#NASDAQ">RGCO</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $26.00 million. 
• Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) is projected to report quarterly loss at $0.21 per share on revenue of $375.22 million. 
• Columbus McKinnon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $252.56 million. 
• Origin Agritech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEED#NASDAQ">SEED</a>) is estimated to report earnings for its Fiscal Year 2024. 
• Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $117.09 million. 
• Unitil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTL#NYSE">UTL</a>) is estimated to report quarterly earnings at $0.95 per share on revenue of $145.00 million. 
• Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $934 thousand. 
• SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) is expected to report quarterly earnings at $0.87 per share on revenue of $169.29 million. 
• Bank of N.T Butterfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTB#NYSE">NTB</a>) is projected to report quarterly earnings at $1.14 per share on revenue of $143.43 million. 
• Simpson Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) is projected to report quarterly earnings at $1.29 per share on revenue of $498.53 million. 
• Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is estimated to report quarterly earnings at $4.10 per share on revenue of $2.78 billion. 
• TIM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIMB#NYSE">TIMB</a>) is estimated to report earnings for its fourth quarter. 
• Vornado Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) is estimated to report quarterly earnings at $0.51 per share on revenue of $447.75 million. 
• Axcelis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) is expected to report quarterly earnings at $1.25 per share on revenue of $244.95 million. 
• Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) is likely to report quarterly loss at $1.10 per share on revenue of $14.09 million. 
• Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) is likely to report quarterly earnings at $1.03 per share on revenue of $280.21 million. 
• Apollo Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $48.20 million. 
• Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $36.05 million. 
• Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $212.45 million. 
• Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $1.66 billion. 
• Danaos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>) is estimated to report quarterly earnings at $6.95 per share on revenue of $261.56 million. 
• Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $1.73 billion. 
• Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $537.61 million. 
• CoreCivic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) is estimated to report quarterly earnings at $0.30 per share on revenue of $465.17 million. 
• NGL Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGL#NYSE">NGL</a>) is estimated to report quarterly earnings at $0.13 per share on revenue of $1.72 billion. 
• Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) is projected to report quarterly earnings at $3.12 per share on revenue of $535.01 million. 
• Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $127.91 million. 
• Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) is estimated to report quarterly earnings at $0.72 per share on revenue of $232.90 million. 
• Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $35.59 million. 
• PennantPark Floating Rate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $59.48 million. 
• Cincinnati Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CINF#NASDAQ">CINF</a>) is expected to report quarterly earnings at $1.87 per share on revenue of $2.63 billion. 
• Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) is projected to report earnings for its fourth quarter. 
• Credicorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAP#NYSE">BAP</a>) is likely to report quarterly earnings at $4.66 per share on revenue of $1.48 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

ACLS

ALAB

AMKR

ARKR

ARWR

CINF

CMCO

COTY

CRESY

CSPI

FLNC

HAIN

HLIT

INSP

ISPR

LSCC

MEDP

MITK

MPAA

PETS

PFLT

PNNT

PSEC

QIPT

RGCO

RICK

RLGT

SEED

SLQT

SPSC

TIMB

TSEM

VRTX

XAIR

Earnings Scheduled For February 10, 2025

RBC Capital analyst Leonid Timashev reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and maintains $70 price target.

RBC Capital Reiterates Sector Perform on Incyte, Maintains $70 Price Target

A significant insider transaction involving the exercise of company stock options was reported on January 22, by Matteo Trotta, EVP at Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), as per the latest SEC filing.
What Happened: A notable Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000879169/000087916925000033//Archives/edgar/data/879169/000087916925000033/0000879169-25-000033-index.htm">U.S. Securities and Exchange Commission</a> revealed that Trotta, EVP at Incyte, exercised stock options for 0 shares of INCY, resulting in a transaction value of $0.
Incyte shares are trading, exhibiting down of 0.76% and priced at $71.86 during Thursday's morning. This values Trotta's 0 shares at $0.
<h3>Discovering Incyte: A Closer Look</h3>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Incyte: A Financial Overview</h3>
Revenue Growth: Incyte displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 23.81%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 92.44%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Incyte's EPS is below the industry average. The company faced challenges with a current EPS of 0.55. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Incyte's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 804.56, Incyte's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 3.83 is lower than the industry average, implying a discounted valuation for Incyte's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 33.47 reflects market recognition of Incyte's value, positioning it as more highly valued compared to industry peers.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000879169">Check Out The Full List Of Incyte's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Decision Unfolding At Incyte: Matteo Trotta Exercises Options, Resulting In $0

A substantial insider activity was disclosed on January 22, as CAGNONI, President at Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), reported the exercise of a large sell of company stock options.
What Happened: The latest Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000879169/000087916925000035//Archives/edgar/data/879169/000087916925000035/0000879169-25-000035-index.htm">U.S. Securities and Exchange Commission</a> uncovered CAGNONI, President at Incyte, exercising stock options for 0 shares of INCY. The total transaction was valued at $0.
During Thursday's morning session, Incyte shares down by 0.76%, currently priced at $71.86. Considering the current price, CAGNONI's 0 shares have a total value of $0.
<h3>About Incyte</h3>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Incyte's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Incyte showcased positive performance, achieving a revenue growth rate of 23.81% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 92.44%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Incyte exhibits below-average bottom-line performance with a current EPS of 0.55.
</li>
</ul>
Debt Management: Incyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 804.56 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.83, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Incyte's EV/EBITDA ratio, surpassing industry averages at 33.47, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000879169">Check Out The Full List Of Incyte's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Notable Insider Move: PABLO CAGNONI Takes Part In Options Exercise At Incyte, Resulting In $0

In a recent SEC filing, it was disclosed that Thomas Tray, Principal Accounting Officer at Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), made a noteworthy acquisition of company stock options on January 22,.
What Happened: Tray, Principal Accounting Officer at Incyte, engaged in a derivative transaction according to a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000879169/000087916925000036//Archives/edgar/data/879169/000087916925000036/0000879169-25-000036-index.htm">U.S. Securities and Exchange Commission</a>. This involved the acquisition of stock options for 3,432 shares of INCY, providing the right to purchase the company's stock at an exercise price of $71.93 per share.
During Thursday's morning session, Incyte shares down by 0.19%, currently priced at $72.27. Considering the current price, Tray's 3,432 shares have a total value of $1,166.
<h3>Get to Know Incyte Better</h3>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Breaking Down Incyte's Financial Performance</h3>
Positive Revenue Trend: Examining Incyte's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.81% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 92.44%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Incyte's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.55.
</li>
</ul>
Debt Management: Incyte's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 804.56, Incyte's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.83 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 33.47 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000879169">Check Out The Full List Of Incyte's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Thomas Tray Expands Holdings With Incyte Stock Options Worth $1K

Christiana Stamoulis, EVP &amp; Chief Financial Officer at Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), reported acquisition of company stock options on January 22, according to a new SEC filing.
What Happened: Stamoulis, EVP &amp; Chief Financial Officer at Incyte, acquired stock options for 25,516 shares of INCY. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000879169/000087916925000039//Archives/edgar/data/879169/000087916925000039/0000879169-25-000039-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The options allow Stamoulis to buy the company's stock at $71.93 per share.
During Thursday's morning session, Incyte shares down by 0.19%, currently priced at $72.27. Considering the current price, Stamoulis's 25,516 shares have a total value of $8,675.
<h3>About Incyte</h3>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Breaking Down Incyte's Financial Performance</h3>
Revenue Growth: Incyte's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.81%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 92.44%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Incyte's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.55.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 804.56, Incyte's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.83 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 33.47 is above the industry average, suggesting that the market values the company more highly for each unit of EBITDA. This could be attributed to factors such as strong growth prospects or superior operational efficiency.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000879169">Check Out The Full List Of Incyte's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In A Strategic Move, Christiana Stamoulis Acquires Incyte Stock Options Worth $8K: Enhancing Value

Press Releases

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

Incyte to Present at Upcoming Investor Conference

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Incyte to Present at Upcoming Investor Conferences

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

Comments

Incyte

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga